Resmetirom was approved in 2024 for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD). Do you know its mechanism of action? The post Which Endocrine Pathway Does Resmetirom Target? […]
The post Which Endocrine Pathway Does Resmetirom Target? first appeared on Blackandmed .
